Days-to-cover ratio for XFOR declines to 0.96 due to decline in short interest


Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. X4 Pharmaceuticals Inc. shares valued at $44,100 were sold by Mostafa Adam S. on Mar 10. At $0.84 per share, Mostafa Adam S. sold 52,500 shares. The insider’s holdings dropped to 93,696 shares worth approximately $0.19 million following the completion of this transaction.

25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Also, Ragan Paula sold 49,678 shares, netting a total of over 41,730 in proceeds. Following the sale of shares at $0.84 each, the insider now holds 563,537 shares.

Before that, DiBiase Mary had sold 18,192 shares from its account. In a trade valued at $15,281, the Chief Operating Officer traded X4 Pharmaceuticals Inc. shares for $0.84 each. Upon closing the transaction, the insider’s holdings decreased to 18,192 shares, worth approximately $0.31 million.

Analyzing XFOR Stock Performance

On Thursday, X4 Pharmaceuticals Inc. [NASDAQ: XFOR] rose 2.03% to $2.01. The stock’s lowest price that day was $1.89, but it reached a high of $2.06 in the same session. During the last five days, there has been a surge of approximately 3.61%. Over the course of the year, X4 Pharmaceuticals Inc. shares have jumped approximately 102.42%. Shares of the company reached a 52-week high of $2.3400 on 05/22/23 and a 52-week low of $0.7800 on 03/28/23. A 50-day SMA is recorded $1.3200, while a 200-day SMA reached $1.2900. Nevertheless, trading volume fell to 3.46 million shares from 6.8 million shares the previous day.

Support And Resistance Levels for X4 Pharmaceuticals Inc. (XFOR)

According to the 24-hour chart, there is a support level at 1.9100, which, if violated, would cause prices to drop to 1.8200. In the upper region, resistance lies at 2.0800. The next price resistance is at 2.1600. RSI (Relative Strength Index) is 61.33 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.1900, which suggests the price will decrease in the coming days. Percent R is at 35.48%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.

Is X4 Pharmaceuticals Inc. subject to short interest?

Stocks of X4 Pharmaceuticals Inc. saw a sharp steep in short interest on May 14, 2023 dropping by -0.58 million shares to 2.95 million. Data from Yahoo Finance shows that the short interest on Apr 13, 2023 was 3.53 million shares. A decline of -19.66% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.96 of the overall float, the days-to-cover ratio (short ratio) decline to 0.96.

Which companies own the most shares of X4 Pharmaceuticals Inc. (XFOR)?

According to Empery Asset Management LP filings, the company currently owns 6,198,684 shares, which is about 5.07% of the total XFOR shares outstanding. AXA Investment Managers UK Ltd. acquire a 0.80% interest valued at $6.46 million while The Vanguard Group, Inc. purchased a 763,922 stake. A total of 171,967 shares of X4 Pharmaceuticals Inc. were bought by Tri Locum Partners LP during the quarter, and 421,590 were bought by Parkman Healthcare Partners LLC. In its current portfolio, Cormorant Asset Management LP holds 1,628,980 shares valued at $2.39 million.

In terms of X4 Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $3.66 in the next 12 months, up nearly 103.05% from the previous closing price of $1.97. Analysts anticipate X4 Pharmaceuticals Inc. stock to reach $5.00 by 2023, with the lowest price target being $2.60. In spite of this, 8 analysts ranked X4 Pharmaceuticals Inc. stock as a Buy at the end of 2023.


Please enter your comment!
Please enter your name here